Benzinga's M&A Chatter for Wednesday August 10, 2016

The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday August 10, 2016:

Lam Research, KLA-Tencor Say Continue to Believe Deal is Pro-Competitive, Beneficial to Customers, Employees, Suppliers

The Comments:
Lam Research Corporation LRCX and KLA-Tencor Corporation KLAC announced Wednesday that they continue to work on receiving the necessary approvals from the DoJ and from competition authorities in Korea, Japan and China. The companies believe the transaction is pro-competitive and beneficial to their respective customers, employees and suppliers.

Lam Research closed Wednesday at $89.11 down 4.5%, while KLA-Tencor closed at $69.47, down more than 10%.

Judge to Start Aetna-Humana Merger Trial on December 5th

The Trial Date:
The U.S. District Court judge hearing the DoJ's case to block Aetna's AET acquisition of Humana HUM has selected December 5, 2016 as the trial date. The healthcare companies had requested an earlier date so that their deal could close within the planned time frame. The judge expects to rule in mid to late January 2017. U.S. District Court Judge Bates said during a hearing Wednesday that Aetna and Humana failed to show how a December trial would cause harm.

Aetna closed at $119.54 on Wednesday, flat. Human rose 1.45%, to close at $179.70.

Mesa Labs Reports Purchase of Cold Chain Manufacturing Capabilities

The Deal:
Mesa Laboratories, Inc. MLAB announced Wednesday, the acquisition of certain assets and liabilities of Rapid Aid Corp by Mesa Canada. Terms were not disclosed.

Mesa Laboratories closed at $103.88 on Wednesday, up $0.11.